Abstract Based on 1,2 O isopropylidene sn glycerol five chiral building blocks containing differently modified glycerol residues were required for the synthesis of the target molecule 2. One of these building blocks is diacylglyceryl b gentiobioside carrying a phosphite residue at 6b O position. Ligation of these five building blocks led to the desired glycerol phosphate backbone to which D alanyl residues were attached, thus generating after O deprotection the target molecule 2, a bisamphiphilic structural variant of Staphylococcus aureus LTA. This compound displayed higher potency in terms of cytokine release by human blood leukocytes than the monoamphiphilic variant LTA. 
For Gram-negative bacteria, LPS is well established as the crucial stimulus of the innate immune system, as injection of LPS into mice causes all known symptoms of sepsis. 1 There is now good evidence that lipoteichoic acid (LTA) from the cytoplasmic membrane of Grampositive bacteria is an immunostimulatory Gram-positive counterpart to LPS. [2] [3] [4] [5] [6] The most frequently isolated Gram-positive pathogen that causes infections is Staphylococcus aureus, 7 and the development of antibiotic resistance in this species is a big problem. 8, 9 Therefore, alternatives and adjuvants to antibiotics are required. To identify these, it is important to understand the pathophysiology of this bacterial infection.
The structure of the S. aureus LTA is shown in Scheme 1. 3, 10, 11 For unequivocal bioactivity assignment, besides an improved isolation procedure, 11 the chemical synthesis of the structurally closely related compound 1a (Scheme 1) was decisive. [3] [4] [5] 12 This compound contains the hydrolytically labile D D-alanine residues in the required ratio with other substituents at a hexameric glycerophosphate backbone. Compound 1a exhibited essentially the same biological activity in terms of initiation of cytokine release by human blood leukocytes as found for the natural product. Whereas the replacement of the D-alanine residues by L-alanine residues as in 1b led to almost complete loss of biological activity. 4 Further structural modifications of LTA 1a, as for instance deletion of the gentiobiose moiety or replacement of the hydrolytically labile ester bond to the D-alanyl residue by a stable amide bond, led only to minor decrease of induction of cytokine release by human blood leukocytes. 5, 13 Thus, the importance of the D D-alanyl residues was displayed. However, none of the investigated structural modifications so far led to an increased induction of cytokine release. For this, optimal presentation of the hydrophilic part of LTA to the receptor should be of utmost importance; therefore, bisamphiphilic compound 2 (Scheme 2) having two diacylglycerol gentiobioside residues at each end of the glycerolphosphate backbone was designed. It was hypothesized that with two lipid anchors, possibly within the same membrane, the epitope presentation should be supported due to sterically improved accessibility to the D-alanyl and the a-O-linked N-acetylglucosamine residues.
U N C O R O
consider the presence of diacylglyceryl gentiobioside, glyceryl 2-N-acetylamino-2-deoxy-a-D D-glucopyranoside, D-alanylated glycerol and 2-O-unsubstituted glycerol residues, respectively, and their sequence specific linkage via phosphorus diester bonds. Also the most important aspect, the lability of the D D-alanyl residues, which are readily cleaved at pH 8.5, is taken into account: as temporary protecting groups in building blocks 5 and 6 4-methoxyphenylmethyl (MPM) groups are chosen; they can be selectively cleaved by oxidation after completion of the backbone synthesis. Ensuing attachment of D-alanyl residues with Z-protected alanine 8 and then complete O-debenzylation will provide the target molecule 2. Building blocks 3 5 and, as substitute for 6 and 7, 2,3-di-O-benzyl-sn-glycerol, 4 were successfully employed in the synthesis of LTAs 1a, b. Because this work has not been reported in detail, 15 the syntheses of compounds 1a, b will also be described.
Synthesis of building block 3
Benzoylation of gentiobiose with benzoyl chloride in pyridine gave an a-, b-mixture of per-O-benzoylated compound 9 (Scheme 3). Treatment of 9 with hydrazinium acetate in DMF permitted chemoselective removal of the anomeric O-benzoyl group furnishing 1-O-unprotected compound 10. Reaction of 10 with trichloroacetonitrile in the presence of 1,8-diazabicyclo[5. 4 .0]undec-7-ene 
General structure A of lipoteichoic acid (LTA) from Staphylococcus aureus (A) and structure of closely related compound 1a and its diastereoisomer 1b.
U N C O R R E C T E D P R O O F
(DBU) as base afforded trichloroacetimidate 11 as a 1:1 anomeric mixture. Glycosylation of 1,2-O-isopropylidene-sn-glycerol (12) 16 with 11 in the presence of BF 3 AEOEt 2 as activator gave exclusively b-glycoside 13 in 80% yield. Complete O-debenzoylation with sodium methoxide in methanol afforded compound 14 which was regioselectively silylated at the primary hydroxy group with tert-butyldiphenylsilyl (TBDPS) chloride in pyridine to give 6b-O-protected compound 15. Following O-benzylation with benzyl bromide and sodium hydride as base in DMF as solvent afforded fully O-protected gentiobioside 16. Acid-catalyzed O-deisopropylidenation (! 17) and then treatment with myristoyl chloride in the presence of triethylamine as base led to introduction of two myristoyl residues furnishing compound 18. 6b-O-Desilylation with tetrabutylammonium fluoride (TBAF) in the presence of acetic acid in THF as solvent gave 6b-O-unprotected compound 19 which on reaction with benzyloxy-bis(diisopropylamino)-phosphane 17 in the presence of tetrazole as catalyst furnished building block 3.
Synthesis of LTA 1a and its diastereomer 1b
With building block 3 and the previously synthesized glycerophosphate oligomer 20, 13 possessing the required protecting group array for regioselective chain extension and for following D-alanyl residue attachment, the synthesis of 1a, b could be readily completed (Scheme 4). Ligation of 3 and 20 in the presence of tetrazole and then oxidation with tert-butylhydroperoxide gave phosphate linked intermediate 21, which contains the backbone of the target molecule. Treatment of 21 with ceric(IV) ammonium nitrate (CAN) liberated four of the glycerol hydroxy groups affording compound 22. Attachment of the Z-protected D-alanyl residues was performed with excess 8 in the presence of (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 18 (PyBOP)/N-methyl-imidazole as condensing agent to give the fully protected target molecule 23a. Hydrogenolysis with Pearlman's catalyst 19 in a mixture of CH 2 Cl 2 /MeOH/H 2 O (5:5:1) furnished the desired final product 1a after hydrophobic interaction (HI) chromatography on actylsepharose in 47% yield. The structural assignment was based on MS and NMR data and comparison with naturally occurring material. 3 Compound 22 was similarly transformed with Z-protected L-alanine via 23b into 1b.
Synthesis of building blocks 6 and 7
Previously described 1-O-(tert-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-sn-glycerol (24), 13 obtained from 1,2-O-isopropylidene-sn-glycerol, was treated with monomethoxytrityl (MMTf) chloride in CH 2 Cl 2 /pyridine to afford fully O-protected glycerol derivative 25 (Scheme 5). Regioselective O-desilylation with TBAF in THF afforded the 1-O-unprotected building block 6.
Treatment of previously described 3-O-allyl-1-O-(tertbutyldiphenylsilyl)-sn-glycerol (26) 13 with benzyl bromide in DMF afforded per-O-protected glycerol 27. ODeallylation with Wilkinson's catalyst 20 in the presence of DBU as base in ethanol furnished the 3-O-propenyl derivative which was cleaved with 1 M HCl in acetone to afford 3-O-unprotected 28. Reaction with MMTr-Cl in CH 2 Cl 2 /pyridine furnished fully protected glycerol 29 which on treatment with TBAF in THF led to 1-Ounprotected glycerol 30. Phosphitylation with benzyloxy-bis(diisopropylamino)phosphane 17 led to the desired phosphite derivative 7.
Synthesis of target molecule 2
The assembly of target molecule 2 from building blocks 3 8 was performed stepwise in solution starting with building block 6 (Scheme 6). Phosphitylation of 6 with 5 in the presence of tetrazole and then oxidation with tert-butylhydroperoxide gave phosphate intermediate 31 which was O-desilylated with TBAF in THF as solvent to furnish 32 with a free hydroxy group as acceptor for the next reaction cycles for chain extension. This way, with 5 intermediates 33 35 were obtained. Following cleavage of the MMTr group with camphersulfonic acid (CSA) in methanol afforded 36 which on phosphitylation 19 in a dichloromethane/methanol/ water mixture as solvent. The crude product was purified by HI chromatography to afford target molecule 2 in 32% yield. Compound 2 was structurally ascertained as all intermediates by NMR and MS data and most intermediates also by elemental analyses.
Biological activity
The evaluation of the biological activity of compound 2 was performed in comparison with compound 1a (Fig. 1) , which induces a similar pattern of cytokine release as natural S. aureus LTA. 3, 4 Measurement of initiation of cytokine release (A, TNFa; B, IL-8) by human blood leukocytes displayed that bisamphiphilic 2 is more potent than monoamphiphilic LTA 1a by a factor of about 10. Hence, the hypothesis that bisamphiphilic LTA analogues should exhibit stronger biological activity than monohomophilic LTA 1a was proven to be correct. 
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Conclusion
In conclusion, retrosynthesis of bisamphiphilic structural variant 2 of S. aureus LTA led to six building blocks out of which five required differently modified chiral glycerol residues. They readily permitted the assembly of compound 2. The backbone construction was based on the ligation of different glycerol phosphites possessing, similar to nucleotide synthesis, temporary O-protecting groups permitting sequence specific chain extension. Hence, based on this synthesis design ready access not only to monoamphiphilic S. aureus LTA 1a, which is also described in detail, but also to a multitude of structural variants of LTA is available. As anticipated, bisamphiphilic compound 2 is more potent in terms of induction of cytokine release in human leukocytes than natural LTA and its shortened version 1a.
5. Experimental
General remarks
Solvents were dried according to standard procedures. NMR spectroscopic measurements were performed at 22°C with Bruker DRX600 and Bruker AC250 instruments. TMS or the resonances of the deuterated solvents were used as internal standard. CDCl 3 (d = 7.24 ppm) was used as external standard; 85% of phosphoric acid was used as external standard for 31 P spectra. MALDI mass spectra were recorded with a Kratos Kompact Maldi II spectrometer; 2,5-dihydroxybenzoic acid (DHB) or p-nitroaniline and NaI were used as matrices for positive measurements, and trihydroxyacetophenone (THAP) was used as matrix for negative mode measurements. Optical rotations were measured with a Perkin Elmer polarimeter 241/MS in a 1-dm cell at 22°C. 
General procedure for phosphate formation
The alcohol and the phosphane (1.2 equiv) were coevaporated with dry CH 2 Cl 2 and dried in high vacuum for 1 h. The mixture was dissolved in dry CH 2 Cl 2 and tetrazole (2.5 equiv, previously dried for 1 h in high vacuum) was added. The reaction mixture was stirred for 1.5 h at room temp (TLC control), and after this time t-BuO 2 H (1.3 equiv of 5.5 M solution in decane) was added. The reaction mixture was stirred for another 30 45 min and diluted with EtOAc, washed with saturated NaHCO 3 solution. The organic phase was dried over MgSO 4 and evaporated in vacuo. Purification by flash chromatography on silica gel gave the desired product.
General procedure for the removal of tert-butyldiphenylsilyl protecting group
The silylated compound was dissolved in THF (p.a. quality) and treated with TBAF (1.2 equiv of 1 M solution in THF). The reaction mixture was stirred for 30 45 min at room temp (monitoring by TLC). After this time, the reaction mixture was diluted with EtOAc and washed with saturated NH 4 Cl solution and water. The organic phase was dried over MgSO 4 and the solvent evaporated in vacuo. Flash chromatography on silica gel gave the desired compound.
Gentiobiose (14.13 g, 41.28 mmol) was dissolved in pyridine (375 mL), benzoyl chloride was added (50 mL, 0.48 mol) and the reaction mixture was stirred at 40°C overnight. The solvent was removed and the crude material purified by flash chromatography (petroleum ether/ EtOAc, 2:1) to give 9 in 98% yield (48 g) as a white solid. 
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A solution of 9 (48 g, 40.85 mmol) in dry DMF (425 mL) was heated to 50°C and hydrazinium acetate was added (5.4 g). After 3.5 h, the solution was diluted with CH 2 Cl 2 and washed with water. The organic phase was dried over MgSO 4 
Compound 10 (32.11 g, 29.98 mmol) was dissolved in dry CH 2 Cl 2 (450 mL), and Cl 3 CCN (30.5 mL, 0.3 mol) was added; subsequently DBU was added (0.45 mL). After 2 h, the solvent was removed in vacuo and the rest was purified by flash chromatography (petroleum ether/ EtOAc 2:1, +1% Et 3 N) to give 11 in 97% of yield 
To a solution of 13 (19.14 g, 16.15 mmol) in dry MeOH (300 mL) and dry CH 2 Cl 2 (20 mL) was added NaH (0.81 g, 33.75 mmol) and stirred at rt. After 12 h, the reaction mixture was neutralized with amberlite IR-120 H + , filtered and evaporated in vacuo with a little amount of Et 3 N. The solid was dissolved in a mixture of dioxane/ water and lyophilized, 14 was obtained in quantitative yield (7. 
To a solution of compound 15 (6.2 g, 8.92 mmol) in 180 mL of dry DMF was added benzyl bromide (10 equiv, 10.6 mL) at 10°C. Then NaH (15 equiv, 2.1 g) was added portionwise, and the reaction mixture was stirred for 2 h at rt. The solvent was evaporated in vacuo; the residue was redissolved in EtOAc and washed two times with saturated NH 4 Cl solution. The organic phase was dried over MgSO 4 
3-O-[6-O-(2,3,4-Tri-O-benzyl-6-O-tert-butyldiphenylsilyl-b-D-glucopyranosyl)-2,3,4-tri-O-benzyl-b-Dglucopyranosyl]-sn-glycerol (17)
To a solution of 16 (4 g, 3.24 mmol) in THF (100 mL), 200 mL of 75% CH 3 H, 5a-H), 3.65 (m, 1 H, 3b-H), 3.68 (m, 1 H, 3a-H 
1,2-
To a solution of compound 17 (3.5 g, 2.93 mmol) in dry THF (140 mL), Et 3 N (4.5 mL, 11 equiv) and myristoyl chloride (4.76 mL, 6 equiv) were added. The reaction mixture was stirred at 50°C; after 4 h it was diluted with EtOAc and washed with saturated NH 4 
1,2-Di-O-myristoyl-3-O-[6-O-(2,3,4-tri-O-benzyl-b-D-glucopyranosyl)-2,3,4-tri-O-benzyl-b-D D-glucopyranosyl]-sn-glycerol (19)
Compound 18 (3.84 g, 2.38 mmol) was dissolved in dry THF (200 mL), CH 3 COOH (0.6 mL, 4 equiv) and TBAF (1 M solution, 9.5 mL, 4 equiv) were added and the reaction mixture was stirred for 72 h at 40°C. The
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reaction mixture was diluted with AcOEt (500 mL) and washed with half saturated NH 4 Cl solution (300 mL), the organic phase was dried over MgSO 4 
[Benzyloxy
Compound 19 (0.7 g, 0.508 mmol) was dried for 1 h together with tetrazole (21.4 mg, 0.6 eq) in high vacuum. Under argon atmosphere benzyloxybis-(diisopropylamino)-phosphane (215 mg, 1.3 equiv) dissolved in 10 mL of dry CH 2 Cl 2 was added. After 30 min of stirring at rt the tetrazole was dissolved, the reaction mixture was stirred for 1.5 h; then the mixture was diluted with CH 2 Cl 2 and poured over a saturated NaHCO 3 solution. The organic phase was dried over MgSO 4 1 C, C-4a), 81.91 82.15 (2 C, C-2a, C-2b) , 84.51 84. 78 (2 C, C-3a, C-3b), 103.65 (1 C, C-1a) , 103.92 103. 98 (1 C, C-1b 
Hexaphosphate 21
Compound 20 13 (494 mg, 0.202 mmol) and phosphite amide 3 (424 mg, 1.3 equiv) were coevaporated each with dry CH 2 Cl 2 (10 mL) and dried for 1 h in high vacuum. Compound 3 was dissolved in 15 mL of dry CH 2 Cl 2 and was added, under argon atmosphere, to compound 20; tetrazole (29 mg, 2 equiv, dried previously for 1 h in high vacuum) was also added. The reaction mixture was stirred at rt under argon atmosphere. After 70 min, t-BuO 2 H (0.6 mL) was added dropwise and the reaction mixture was stirred for another 35 min CH 2 Cl 2 was added and the mixture was washed with saturated NaHCO 3 solution, the organic phase was dried over MgSO 4 1 C, C-4c), 78.2 (1 C, C-2), 81.2 (1 C, C-3c) , 81.8 
Hexaphosphate 22
Compound 21 (417 mg, 0.105 mmol) was dissolved in acetonitrile/toluene/water (60:3:4, 20 mL) and cooled to À10°C. Ce(NH 4 ) 2 (NO 3 ) 6 (1.15 g, 20 equiv) was added portionwise and the reaction mixture was stirred for 20 min at À10°C, the cooling bath was removed and the reaction mixture was stirred for another 30 40 min (TLC-monitoring). After this time, the reaction mixture was diluted with EtOAc and washed with saturated NaHCO 3 solution, the organic phase was dried over MgSO 4 
Target molecule 1a
The diastereomers 23a (83 mg, 0.019 mmol) were dissolved in CH 2 Cl 2 /MeOH/H 2 O (7.5:7.5:1.5, 6 mL), treated with Pearlman's catalyst (10% in weight) and under hydrogen atmosphere, with a H 2 -filled balloon, was stirred overnight at rt. The reaction mixture was filtered through Celite, washed with CH 2 Cl 2 /MeOH/H 2 O (7.5:7.5:1.5, 2 mL) and the filtrate was diluted with 0.1 M NH 4 OAc-buffer (pH 4.8). The solvent was lyophilized and purified using hydrophobic interaction HPLC on octylsepharose. After lyophilization, compound 1a (20 mg, 47%) was obtained as white powder.
[a] D +6.9 0 -H). 13 
Target molecule 1b
Compound 1b was obtained using the same procedure as for 1a. , 1 H, 1c-H + , m/z = 2249.9; found: m/z = 2249.9.
Compound 24 13 (3.56 g, 7.9 mmol) was dissolved in CH 2 Cl 2 /pyridine (1:1, 80 mL), monomethoxytrityl chloride was added and the reaction mixture was stirred overnight at rt. The solvent was removed in vacuo and the residue was dissolved in EtOAc, washed with saturated NaHCO 3 
2-O-(4-Methoxybenzyl)-3-O-monomethoxytrityl-snglycerol (6)
Compound 25 (5.5 g, 7.6 mmol) was dissolved in THF (100 mL) and TBAF (9.1 mL, 1 M, 1.2 equiv) was added dropwise. The reaction mixture was stirred for 2 h at rt, and the solution was diluted with EtOAc, washed with water, saturated NaHCO 3 solution and dried over 
2-O-Benzyl-1-O-tert-butyldiphenylsilyl-sn-glycerol (28)
Compound 27 (13.3 g, 28.9 mmol) was dissolved in dry EtOH (300 mL), DBU (648 lL, 0.15 equiv) and (Ph 3 P) 3 RhCl (8 g, 0.3 equiv) were added and the reaction mixture was stirred at 90°C. After 15 min, the propenyl intermediate was formed (R f = 0.76, toluene/ acetone 1.5:1); the solvent was removed in vacuo and the residue was dissolved in a solution of 1 M HCl/acetone (1:9, 200 mL) and stirred at 70°C for 15 min. The solution was neutralized with NEt 3 , diluted with EtOAc and washed with saturated NaHCO 3 solution. After drying with MgSO 4 , the solvent was removed in vacuo. Flash chromatography (petroleum ether/EtOAc 3:1) yielded 28 (9.2 g, 76 %) as a yellow syrup. The analytical data are in accordance with those reported in the literature. 21 
2-O-Benzyl-3-O-monomethoxytrityl-1-O-(tert-butyldiphenylsilyl)-sn-glycerol (29)
Compound 29 was obtained as described for 25. 
Compound 31
Compound 31 was synthesized following the general coupling procedure. Compound 6 (3.59 g, 7.41 mmol), tetrazole (780 mg, 11.14 mmol) and phosphite amide 5 13 (5.6 g, 1.1 equiv) were dissolved in dry CH 2 
